MilliporeSigma has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress Lentiviral Production Platform. According to the company, this new platform helps to overcome lentiviral production challenges and can reduce process development time by approximately 40 percent, based on MilliporeSigma’s experience as a contract development and manufacturing organization (CDMO).   “Cell and gene therapies offer the potential for curative treatments and are being develo...